Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Handbook of Anticancer Drug Development

Handbook of Anticancer Drug Development

9780781740104
384.30 zł
345.87 zł Save 38.43 zł Tax included
Lowest price within 30 days before promotion: 345.87 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Written by leading investigators from academia and the pharmaceutical industry, this volume is a comprehensive, practical guide for all researchers involved in anticancer drug development. The book covers the entire field from preclinical research, through clinical trials, to licensure requirements in the United States and in the European Union.

Chapters address drug discovery, preclinical models, drug measurement, delivery systems, Phase I trial design, and Phase II-III testing. The book provides state-of-the-art coverage of contemporary drug design concepts, in vitro models, new assay methodologies, good manufacturing practice criteria in the US and EU, and new methods for testing anticancer agents in humans.

Product Details
Lippincott Williams & Wilkins
38896
9780781740104
9780781740104

Data sheet

Publication date
2003
Issue number
1
Cover
hard cover
Pages count
400
Dimensions (mm)
178 x 254
Weight (g)
984

  • Part 1:: Introduction

  • How Oncology Drug Development Differs from Other Fields, 3
    Ann T. Farrell, John Leighton, Grant Williams, and Richard Pazdur

    Part 2:: Drug Discovery

  • Natural Products, 13
    Riyaz N.H. Shah and Stanley B. Kaye
  • History of the National Cancer Institute Drug Discovery Program, 25
    Edward A. Sausville and Jill I. Johnson
  • Combinatorial Chemistry in Anticancer Drug Development, 43
    Ian R. Hardcastle and Roger J. Griffin
  • Protein Crystallography in Drug Discovery, 57
    Martin Noble and Jane Endicott
  • High-Throughput Screening, 69
    Ramesh Padmanabha and Martyn Banks
  • Bioinformatics and Data Mining in Support of Drug Discovery, 79
    Jeffrey Augen
  • Genomics and Drug Development, 97
    Robert H. tePoele and Paul Workman
  • The Application of Proteomics to Drug Development, 117
    Lasantha R. Bandara and Sandy Kennedy

    Part 3:: Preclinical Models

  • The Role of In Vitro Cell Line, Human Xenograft, and Mouse Allograft Models in Cancer Drug Development, 129
    Theodora Voskoglou-Nomikos, Stefan D. Baral, and Lesley K. Seymour
  • Drug-Drug Interaction Studies During Early Clinical Drug Development, 149
    Jochen Kuhlmann and Christoph Wandel
  • Gene-Targeted Mice in Anticancer Drug Development, 163
    Thomas M. Donnelly

    Part 4:: Analytical Laboratory Techniques

  • Modern and Practical Guide for Bioanalysis, 187
    Surendra K. Bansal and Zhenmin Liang
  • Good Laboratory Practice and the Development of Anticancer Agents, 195
    Jinee D. Rizzo

    Part 5:: Delivery Systems

  • Pharmaceutical Formulation of Novel Anticancer Agents, 205
    Bastiaan Nuijen
  • Liposomal Drug Carriers for Cancer Diagnosis and Therapy, 225
    Martin Brandl
  • Polymer-Drug Conjugates, 239
    Ruth Duncan
  • Prodrug Drug Development and Retrometabolic Engineering, 261
    Daniel R. Budman
  • Pharmacokinetics and Pharmacodynamics in Anticancer Drug Development, 269
    Chris H. Takimoto

    Part 6:: Clinical Studies

  • Allometric Scaling:: Predicting Pharmacokinetic Parameters of Drugs in Humans from Animals, 285
    Iftekhar Mahmood
  • Phase I Clinical Trial Design, 297
    Lawrence V. Rubinstein and Richard M. Simon
  • Phase I Trial Design:: Considerations in the Pediatric Population, 309
    Elizabeth Fox and Peter C. Adamson
  • Measurements of Endpoints in Phase I Drug Design:: Toxicity versus Alternatives, 319
    Jerry M. Collins and Merrill J. Egorin
  • Tumor Response Evaluation in Clinical Trials:: RECIST, 331
    A. Dimitrios Colevas
  • Pharmacogenetics and Cancer Chemotherapy, 343
    Hany Ezzeldin and Robert B. Diasio
  • Designs for Phase II and Phase III Cancer Drug Studies, 379
    Gary L. Rosner and Donald A. Berry

    Part 7:: Specific Issues in Drug Development

  • Data Verification and Scientific Auditing, 395
    Raymond B. Weiss
  • Role of the Cooperative Groups in Drug Development, 403
    Christopher W. Ryan and Richard L. Schilsky
  • Drug Development in the Elderly, 411
    Stuart M. Lichtman
Comments (0)

  • Frequently purchased together

    No products available